KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Curent Deferred Tax Liability: 2014

Historic Curent Deferred Tax Liability for Alnylam Pharmaceuticals (ALNY) over the last 1 years, with Dec 2014 value amounting to $31.7 million.

  • Alnylam Pharmaceuticals' Curent Deferred Tax Liability was N/A to $9.4 million in Q3 2015 from the same period last year, while for Sep 2015 it was $9.4 million, marking a year-over-year change of. This contributed to the annual value of $31.7 million for FY2014, which is N/A change from last year.
  • As of FY2014, Alnylam Pharmaceuticals' Curent Deferred Tax Liability stood at $31.7 million.
  • In the past 5 years, Alnylam Pharmaceuticals' Curent Deferred Tax Liability registered a high of $31.7 million during FY2014, and its lowest value of $31.7 million during FY2014.
  • For the 1-year period, Alnylam Pharmaceuticals' Curent Deferred Tax Liability averaged around $31.7 million, with its median value being $31.7 million (2014).